采用GastroPlus 软件发表的部分参考文献汇总 (2023年7-12月)
采用GastroPlus 软件发表的部分参考文献汇总
(2023年7-12月)
导读
凡默谷技术部挑选了2023年7-12月全球采用GastroPlus 软件发表或涉及GastroPlus的部分应用文章。希望对您的业务或专业学习有所帮助。
如您想了解某篇文章的详情,请下载《采用GastroPlus 软件发表的部分参考文献汇总列表-2023年7-12月》PDF版文件,有对应文章的介绍链接。
2023年7-12月 PDF版文献汇总列表下载
https://www.jianguoyun.com/p/DaQb4F8Q_a64Bxjp1bIFIAA
(复制链接到浏览器)
01
中国用户发表的部分文章
采用生理药代动力学模型评估阿那帕唑与克拉霉素和阿莫西林在接受幽门螺杆菌感染根除治疗的患者中的药物相互作用
Physiologically based pharmacokinetic modeling to assess the drug-drug interactions of anaprazole with clarithromycin and amoxicillin in patients undergoing eradication therapy of H. pylori infection
Liang N, Zhou S, Tongtong Li, Zhang Z, Zhao T, Li R, Li M, Shao F, Wang G, Sun J. Eur J Pharm Sci. Volume 189, 1 October 2023, 106534. IF=4.6
采用基于生理的药代动力学吸收模型预测华法林的生物等效性并建立其体外溶出的生物等效性安全空间
Predicting bioequivalence and developing dissolution bioequivalence safe space in vitro for warfarin using a Physiologically-Based pharmacokinetic absorption model
Cheng ZZ, Hu X, Li YL, Zhang L. Eur J Pharm Biopharm. Volume 191, October 2023, Pages 12-25. IF=4.9
采用基于生理的吸收模型预测西洛他唑两种制剂的生物等效性
Physiologically based absorption modeling to predict the bioequivalence of two cilostazol formulations
Lu Wang, Pengfei Zhao, Ting Luo, Dandan Yang, Qianqian Jiang, Jinliang Chen, Honggang Lou, Zourong Ruan, Bo Jiang. Clinical and Translational Science. Volume16, Issue11. November 2023. CiteScore=5.7
通过生理药代动力学建模表征噻虫胺的肠肝再循环,并预测食物对它的药代动力学的影响
Physiologically based pharmacokinetic modeling to characterize enterohepatic recirculation and predict food effect on the pharmacokinetics of hyzetimibe
Chen W, Ruan Z, Lou H, Yang D, Chen J, Shao R, Jiang B. Eur J Pharm Sci. Volume 190, 1 November 2023, 106576. IF=4.6
通过GastroPlus 软件预测阿托伐他汀片生物等效性
In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software
Wang L, Chen J, Chen W, Ruan Z, Lou H, Yang D, Jiang B. BMC Pharmacol Toxicol. 24, Article number: 69 (2023). IF=2.9
生理药代动力学模型结合反向剂量法研究他克莫司肾毒性耐受剂量
Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus
Limin Cai1, Meng Ke, Han Wang, Wanhong Wu, Rongfang Lin, Pinfang Huang,·Cuihong Lin. Archives of Toxicology (2023) 97:2659–2673. IF=6.1
生理药代动力学建模在小分子靶向抗癌药物研究中的应用
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
Wang X, Chen F, Guo N, Gu Z, Lin H, Xiang X, Shi Y, Han B. Cancer Chemother Pharmacol. Volume 92, pages 253–270, (2023). IF=3.0
基于生理学的毒物动力学模型在健康风险评估中的应用
The Application of a Physiologically Based Toxicokinetic Model in Health Risk Assessment
Mengting Chen, Ruihu Du, Tao Zhang, Chutao Li, Wenqiang Bao, Fan Xin, Shaozhang Hou, Qiaomei Yang, Li Chen, Qi Wang, An Zhu. Toxics. 2023, 11. IF=4.6
基于生理学的药动学/生物药剂学模型在中药药动学研究中的应用进展
田锁燕,贾国香,胡静雯,卢倩,苏布达,杨珅珅,李遇伯.《中草药》2023年10月 第54卷 第20期. 综合影响因子3.18
基于生理药动学模型定量分析P-糖蛋白对阿哌沙班吸收的影响
李亚梅,谢潘潘,张瑜,陈志兴,史爱欣. 《中国药学杂志》. 2023,58 (15). 综合影响因子1.251
生理药动学模型预测国产左羟丙哌嗪胶囊体外溶出特性及对体内药动学影响
石笑弋,刘轶,兰文,李昌亮,李琦,刘雁鸣,李帅,陈涛. 《中南药学》 2023年7月第21卷第7期. 综合影响因子 0.911
口服药物吸收分数的评价及影响因素综述
张萍,毕福林,杨劲. 《药学学报》 2023. 综合影响因子 1.815
基于化合物结构预测人体ADME/PK性质的效能评价
罗燕,陈涛,王钰玺,任洪灿,高婕,吴卓璟,王晨. 《中国药事》. 2023,37(07). 综合影响因子 1.06
02
其他国家用户发表的部分文章, 或涉及到的综述
采用PBBM证明溶出更快对药品安全性和PK影响的新应用:一个应用案例和其在监管申报中的证明效用
Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics – a case study and utility in regulatory justifications
Boddu R, Kollipara S, Bhattiprolu AK, Ahmed T. Xenobiotica. Volume 53, 2023 - Issue 10-11. IF=1.8
基于生理的生物药剂学PBBM建模在豁免餐后状态下的生物等效性研究中的作用:法规监管展望,应用案例,未来发展前景
Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives
Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini AK, Ahmed T. J Pharm Sci. Available online 1 December 2023. IF=3.8
通过体外数据、生理药代动力学PBPK建模和甲状腺激素动力学模型,考察氟氧芬对甲状腺激素合成的破坏,并进行跨物种外推
Cross species extrapolation of the disruption of thyroid hormone synthesis by oxyfluorfen using in vitro data, physiologically based pharmacokinetic (PBPK), and thyroid hormone kinetics models
Decrane R, Stoker T, Murr A, Ford J, El-Masri HA. Curr Res Toxicol. Volume 5, 2023, 100138. IF=3.3
士的宁作为醛酮还原酶家族1成员B1和B10潜在抑制剂的再利用:计算建模和药代动力学分析
Repurposing of Strychnine as the Potential Inhibitors of Aldo–keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M, Aziz M, Afzal S, Channar PA, Alsfouk BA, Kandhro GA, Hassan S, Sultan A, Hamad A, Arafat M, Qaiser MN, Ahmed A, Siddique F, Ejaz SA. Protein J. 2023 Nov 8. IF=3.0
分子药剂学的声音:会见Bart Hens博士,一位注重多学科联系的社交科学家,解开口服药物在人体胃肠道中的知识缺口
Voices in Molecular Pharmaceutics: Meet Dr. Bart Hens, A Sociable Scientist Focusing on Multidisciplinary Connections to Unravel the Gaps of Oral Drug Behavior in the Human Gastrointestinal Tract.
Hens B. Mol Pharm. 2023 Nov 8. IF=4.9
使用不同的生理药代动力学建模平台比较单克隆抗体预测体内处置的性能
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.
De Sutter PJ, Gasthuys E, Vermeulen A. J Pharmacokinet Pharmacodyn. 2023 Nov 12. IF=2.5
动态肠道吸收模型(Diamod)对以患者为中心的药物制剂处方开发的贡献
Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation.
Moens F, Larsson A, De Blaiser A, Vandevijver G, Spreafico F, Nicolas JM, Lacombe L, Segregur D, Flanagan T, Berben P. Mol Pharm. 2023 Nov 13. IF=4.9
生理药代动力学模型在妊娠期的应用:其可用性和局限性的迷你综述
Physiologically Based Pharmacokinetic modelling of drugs in pregnancy: A mini-review on availability and limitations.
Berezowska M, Sharma P, Pilla Reddy V, Coppola P. Fundam Clin Pharmacol. 2023 Nov 15:e12967. CiteScore = 5.1
预测反义寡核苷酸的药代动力学和药效学: 各种PBPK/PD建模方法和机会的综述
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling.
Gao X, Diep JK, Norris DA, Yu RZ, Geary RS. Expert Opin Drug Metab Toxicol.2023 Nov 16:1-12. IF=4.3
SHIP1治疗靶点的落地:用于治疗迟发型阿尔茨海默病的抑制剂的鉴定和评估
SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease.
Jesudason CD, Mason ER, Chu S, et al. Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI). 2023 Nov 17; 9(4): e12429. CiteScore = 8.9
利用计算方法实现TIM-1模型的数字化──第二部分:GastroPlus中的数字TIM-1模型
Digitalizing the TIM-1 Model Using Computational Approaches ─ Part Two: Digital TIM-1 Model in GastroPlus.
Hens B, Sarcevica I, Tomaszewska I, McAllister M. Mol Pharm. 2023 Nov 6;20(11):5429-5439. IF=4.9
桥接APX3330的群体药代动力学及半机制性吸收模型
Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330.
Silva LL, Stratford RE, Messmann R, Kelley MR, Quinney SK. CPT Pharmacometrics Syst Pharmacol. 2023 Oct 26. CiteScore = 5.9
在缓释药品的生理药代动力学模型中考虑结肠吸收的方法
Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
Jadhav H, Augustijns P, Tannergren C. Mol Pharm. 2023 Oct 30. IF=4.9
Hermansky-Pudlak综合征肺纤维化候选药物S-MRI-1867的体外和体内药代动力学表征、手性转换和PBPK外推到人体PK的模拟
In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis.
Padilha EC, Yang M, Shah P, Wang AQ, Duan J, Park JK, Zawatsky CN, Malicdan MCV, Kunos G, Iyer MR, Gaucher G, Ravenelle F, Cinar R, Xu X. Biomed Pharmacother. 2023 Dec; 168:115178. IF=7.5
通过成人和儿童的基于生理的生物药剂学建模,来解释拉莫三嗪速释制剂的吸收过程
Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.
Caleffi-Marchesini ER, Herling AA, Macente J, Bonan RH, de Freitas Lima P, Moreno R, Alexandre V, Charbe NB, Borghi-Pangoni FB, Cristofoletti R, Diniz A. CPT Pharmacometrics Syst Pharmacol. 2023 Nov 2. CiteScore = 5.9
槲皮素包封磁脂质体:制备、优化、表征和抗氧化研究
Quercetin-encapsulated magnetoliposomes: Fabrication, optimization, characterization, and antioxidant studies.
Kar S, Das SS, Kumar Singh S. Eur J Lipid Sci and Tech. 2023 Oct 30. CiteScore = 5.9
使用计算机方法预测口服混悬液的生物利用度:一种法规监管的方法
Use of In silico Methodologies to Predict the Bioavailability of Oral Suspensions: A Regulatory Approach.
Honório TDS, Simon A, Machado RMC, Rodrigues CR, do Carmo FA, Cabral LM, de Sousa VP. Curr Pharm Des. 2023 Nov 8. IF=3.1
预测酸碱性质、溶解度和食物对生物等效性研究结果影响的潜力:128项研究的分析
Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies.
Krajcar D, Jereb R, Legen I, Opara J, Grabnar I. Drugs R D. 2023 Jun 10. IF=3.0
用计算机模拟的方法开发氢氯噻嗪片和缬沙坦片剂具有区分力的溶出方法
Development of a Discriminative Dissolution Method, Using In-Silico Tool for Hydrochlorothiazide and Valsartan Tablets.
Leon RM, Issa MG, Duque MD, Daniel JSP, Ferraz HG. Pharmaceutics. 2023 Jun 14;15(6):1735. IF=5.4
通过生理药代动力学PBPK模型考察口服药物在老年人的体内吸收-AGePOP综述
Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review.
Demeester C, Robins D, Edwina AE, Tournoy J, Augustijns P, Ince I, Lehmann A, Vertzoni M, Schlender JF. Eur J Pharm Sci. 2023 Jun 15:106496. IF=4.6
通过体外和计算方法来支持口服药品的开发: 来自制药界的评论
Leveraging The Use Of In Vitro And Computational Methods To Support The Development Of Enabling Oral Drug Products: An Inpharma Commentary.
Reppas C, Kuentz M, Bauer-Brandl A, et al. Eur J Pharm Sci. 2023 Jun 19:106505. IF=4.6
基于模型的方法支持仿制药的监管提交-实操中的考虑要点和应用案例
Modelling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies.
Karnati P, Murthy A, Gundeti M, Ahmed T. AAPS J. 2023 Jun 23;25(4):63. IF=4.5
重新审视复杂注射制剂的计算机建模的体外和体内考虑
Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products.
Dabke A, Ghosh S, Dabke P, Sawant K, Khopade A. J Control Release. 2023 Jun 24; 360:185-211. IF=10.8
采用生理药代动力学模型预测CYP介导的药物相互作用:沙丁胺醇和氟伏沙明的应用案例
Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine.
Marques L, Vale N. Pharmaceutics. 2023 15(6):1586. IF=5.4
二甲双胍抑制消化蛋白酶并损害小鼠的蛋白质消化
Metformin inhibits digestive proteases and impairs protein digestion in mice
Kelly CJ, Verdegaal AA, Anderson BW, Shaw WL, Bencivenga-Barry NA, Folta-Stogniew E, Goodman AL. J Biol Chem UME 299, ISSUE 12, 105363, DECEMBER 2023. IF=4.8
采用综合的生理药代动力学PBPK模型评估苯妥英的药物-药物相互作用
Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
Rodriguez-Vera L, Yin X, Almoslem M, Romahn K, Cicali B, Lukacova V, Cristofoletti R, Schmidt S. Pharmaceutics. 2023, 15(10), 2486. IF=5.4
一种强效的甲硫氨酸氨基肽酶2可逆抑制剂M8891的临床前PK和转化PK/PD建模
Preclinical Pharmacokinetics and Translational Pharmacokinetic /Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2
Lignet F, Friese-Hamim M, Jaehrling F, El Bawab S, Rohdich F. Pharm Res. IF=3.7
新型5-HT4受体激动剂DA-6886在犬体内的药代动力学
Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs
Lee DY, Kang HE. Xenobiotica. Volume 53, 2023 - Issue 5. IF=1.8
比较粒径减小、不同盐型、无定型制剂对弱碱性候选药物的生物药剂学性能的影响的评价
Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate
Zhang W, Jia W, Weitz BW, Ma F, Chen Y, Chiang PC, Hou HH, Nagapudi K. Mol Pharm 2023, 20, 11, 5888–5900. IF=4.9
环丙沙星掩味咀嚼片的制剂处方开发、体内生物等效性和儿童PBPK模型的研究
Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets
Usmani MT, Shoaib MH, Siddiqui F, Ahmed FR, Yousuf RI, Saleem MT. Scientific Reports volume 13, Article number: 16070 (2023). IF=4.6
采用生理药代动力学PBPK模型预测恩可非尼的药物相互作用第一部分:酶抑制剂、诱导剂和转运体抑制剂的模型构建、验证和前瞻性预测
Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors
Sivacharan K, Ahmed T, Praveen S. Xenobiotica. Volume 53, 2023 - Issue 5. IF=1.8
采用生理药代动力学PBPK模型预测恩可非尼的药物相互作用第二部分:与临床抑制剂和诱导剂联合用药后对肝损和肾损人群的前瞻性预测
Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers
Kollipara S, Ahmed T, Praveen S. Xenobiotica. Volume 53, 2023 - Issue 5. IF=1.8
用于减肥手术后的选择性COX-2抑制剂:塞来昔布、依托昔布和依托度酸在减肥后人群的溶解度/溶出度和药代动力学
Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics
Porat D, Dukhno O, Partook-Maccabi M, Vainer E, Cvijić S, Dahan A. Int J Pharm. Volume 645, 15 October 2023, 123347. IF=5.8
埃洛石纳米管-纤维素醚基生物复合基质,一种用于BCS一类药物盐酸维拉帕米的潜在缓释给药系统: 压片特征,体外释放动力学,基于PBPK的体内机制研究
Halloysite nanotubes-cellulose ether based biocomposite matrix, a potential sustained release system for BCS class I drug verapamil hydrochloride: Compression characterization, in-vitro release kinetics, and in-vivo mechanistic physiologically based pharmacokinetic modeling studies
Husain T, Shoaib MH, Ahmed FR, Yousuf RI, Siddiqui F, Saleem MT, Farooqi S, Jabeen S. International Journal of Molecular Sciences. Volume 251, 1 November 2023, 126409. IF=8.2
用于研究妊娠期药代动力学的微流控技术与模拟模型
Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy
Kammala AK, Richardson LS, Radnaa E, Han A, Menon R. Front Pharmacol. Volume 14 – 2023. IF=5.6
三种蛋白结合高端紫外滤光剂的ADME表征及PBK模型的建立
ADME characterization and PBK model development of 3 highly protein-bound UV filters through topical application
Li H, Bunglawala F, Hewitt NJ, Pendlington R, Cubberley R, Nicol B, Spriggs S, Baltazar MT, Cable S, Dent M. Toxicological Sciences. Volume 196, Issue 1, November 2023, Pages 1–15. IF=3.8
羟氯喹吸入气凝胶的体外、体内和PBPK评价,一种新型肺靶向给药且心脏安全的新药
The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel
Alsmadi MM, Jaradat N, Obaidat RM, Alnaief M, Tayyem R, Idkaidek N. AAPS PharmSciTech. Volume 24, article number 172, (2023). IF=3.3
计算机建模方法结合药物体外表征数据来预测药物传递系统制剂处方的体内性能
In Silico Modeling Approaches Coupled with In Vitro Characterization in Predicting In Vivo Performance of Drug Delivery System Formulations
Kambayashi A. Molecular Pharmaceutics 2023, 20, 9, 4344–4353. IF=4.9
生物药剂学风险评估—将生物利用度关键属性与体外,体内性质,基于生理的生物药剂学建模关联起来,以实现仿制药的法规监管申报提交
Biopharmaceutics Risk Assessment—Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions
Ahmed T, Kollipara S, Boddu R, Bhattiprolu AK. AAPS J. Volume 25, article number 77, (2023). IF=4.5
开发最佳PBPK模型的先进工具和关键策略,旨在更好地实现体外-体内相关性
Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro–in vivo correlation
Gollhar A, Pillai N, Dhakne P, Rajput N, Jadav T, Sengupta T. Int J Pharm. Volume 643, 25 August 2023, 123267. IF=5.8
整合PBPK与PBBM(PBPK- BM)模型的力量:用于预测食物的影响,性别的影响,药物相互作用,空腹和餐后状态下的生物等效性的单一模型
Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions
Boddu R, Kollipara S, Vijawargi G, Ahmed T. Xenobiotica. Volume 53, 2023 - Issue 4. IF=1.8
采用基于生理的生物药剂学PBBM模型和生物等效性安全空间开发环苯扎林的缓释制剂
Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space
dos Santos EM, Ferraz HG, Issa MG, Duque MD. J Pharm Pharm Sci. Volume 112, Issue 12, December 2023, Pages 3131-3140. IF=3.8
在PBPK模型中引入双相溶出数据,获得先进的体内预测
Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models
Denninger A, Becker T, Westedt U, Wagner KG. Pharmaceutics 2023, 15(7), 1978. IF=5.4
包裹生物聚合物的吡嗪酰胺-载药胶体-体外表征和生物利用度研究
Biopolymer-Capped Pyrazinamide-Loaded Colloidosomes: In Vitro Characterization and Bioavailability Studies
Singh A, Das SS, Ruokolainen J, Kesari KK, Singh SK. ACS Omega 2023, 8, 28, 25515–25524. IF=4.1
PBPK模型作为种间外推的一种替代方法,从而减少了试验动物的使用:系统性综述
PBPK Modeling as an Alternative Method of Interspecies Extrapolation that Reduces the Use of Animals: A Systematic Review
Dayana Lancheros K, Alves I, Aragón M. Curr Med Chem. Volume 31, Number 1, 2024, pp. 102-126(25). IF=4.1
盐酸心得安黏附口腔膜的体外、体内、计算机建模的结合研究
Integrated in vitro – in vivo – in silico studies in the pharmaceutical development of propranolol hydrochloride mucoadhesive buccal films
Kurcubic I, Djuriš J, Cvijić S, Crevar M, Ibric S, Miloradovic Z, Mihailovic-Stanojevic N, Karanovic D, Ivanov M, Jovovic D, Vajic UJ. J Drug Deliv Sci Technol. Volume 86, September 2023, 104715. IF=5.0